Analysts Expect American Renal Associates Holdings Inc (ARA) Will Post Quarterly Sales of $208.40 Million

Analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to post sales of $208.40 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $204.00 million and the highest estimate coming in at $213.20 million. American Renal Associates reported sales of $194.67 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.1%. The business is scheduled to announce its next earnings report on Tuesday, May 14th.

On average, analysts expect that American Renal Associates will report full-year sales of $885.53 million for the current financial year, with estimates ranging from $862.60 million to $910.00 million. For the next fiscal year, analysts expect that the business will report sales of $954.11 million, with estimates ranging from $919.32 million to $984.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for American Renal Associates.

Several brokerages have recently issued reports on ARA. Zacks Investment Research downgraded shares of American Renal Associates from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Leerink Swann downgraded shares of American Renal Associates to a “market perform” rating in a report on Monday, March 11th. SunTrust Banks downgraded shares of American Renal Associates from a “buy” rating to a “hold” rating and set a $10.46 price objective for the company. in a report on Monday, March 11th. ValuEngine downgraded shares of American Renal Associates from a “sell” rating to a “strong sell” rating in a report on Monday, March 11th. Finally, Svb Leerink downgraded shares of American Renal Associates from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. American Renal Associates has a consensus rating of “Hold” and an average target price of $15.64.

Shares of ARA stock traded up $0.18 during trading hours on Friday, reaching $6.54. The stock had a trading volume of 187,445 shares, compared to its average volume of 218,510. The company has a quick ratio of 1.00, a current ratio of 1.03 and a debt-to-equity ratio of 5.48. American Renal Associates has a twelve month low of $5.48 and a twelve month high of $23.99. The stock has a market cap of $203.58 million, a PE ratio of 10.15 and a beta of 2.08.

Several hedge funds have recently added to or reduced their stakes in ARA. Bank of New York Mellon Corp boosted its position in American Renal Associates by 6.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 56,098 shares of the company’s stock worth $1,215,000 after acquiring an additional 3,365 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of American Renal Associates by 17.1% in the 3rd quarter. BlackRock Inc. now owns 955,892 shares of the company’s stock valued at $20,693,000 after buying an additional 139,789 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of American Renal Associates by 39.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 690,103 shares of the company’s stock valued at $14,941,000 after buying an additional 194,395 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of American Renal Associates by 1.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 691,555 shares of the company’s stock valued at $14,972,000 after buying an additional 12,549 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of American Renal Associates in the 3rd quarter valued at approximately $230,000. Institutional investors own 93.96% of the company’s stock.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.